维拉佐酮暴露的回顾:聚焦5-羟色胺综合征效应
本研究通过回顾美国中毒控制中心国家中毒数据系统(NPDS)52个月内的3192例维拉佐酮人类暴露(其中1734例为单药暴露)及毒理学调查者联盟(ToxIC)登记的23例暴露,并附4例病例系列。NPDS中常见效应为嗜睡(20%)、呕吐(14%)、心动过速(11%)和激越(10%),71%症状持续2至24小时,14%超过24小时;最常见治疗为静脉补液(15%),最严重为插管(2%)。ToxIC登记中9例(39%)记录到5-羟色胺综合征,其中8例(89%)以维拉佐酮为主要药物;病例系列4例急性维拉佐酮中毒者全部出现5-羟色胺综合征。结论认为维拉佐酮过量与5-羟色胺综合征相关,临床应予以考虑。
要点
- NPDS 52个月内共报告3192例维拉佐酮人类暴露,其中1734例(54%)为单药暴露。
- 维拉佐酮中毒常见临床效应:嗜睡20%、呕吐14%、心动过速11%、激越10%。
- 71%的患者症状持续2至24小时,14%的患者症状持续超过24小时。
- ToxIC登记中23例维拉佐酮暴露有9例(39%)记录到5-羟色胺综合征,其中8例(89%)以维拉佐酮为主要药物。
- 病例系列中4例急性维拉佐酮中毒患者全部出现5-羟色胺综合征。
适用人群与场景
- 维拉佐酮暴露的患者,包括单药摄入者。
处置流程与药物剂量
- 最常见治疗为静脉补液(15%);最严重治疗为插管(2%)。
研究设计与关键结果
- 研究类型为回顾性综述,数据来自NPDS和ToxIC登记两个数据库,并附4例病例系列;研究周期52个月。
- NPDS共报告3192例维拉佐酮人类暴露,其中1734例(54%)为单药暴露。
- NPDS中临床效应包括嗜睡(20%)、呕吐(14%)、心动过速(11%)和激越(10%)。
- 71%的患者症状持续2至24小时,14%的患者症状持续超过24小时。
- 最常见治疗为静脉补液(15%),最严重为插管(2%)。
- ToxIC登记共识别23例维拉佐酮暴露,其中17例(74%)将维拉佐酮列为第一(主要)药物,10例(43%)为单药摄入。
- ToxIC登记中9例(39%)记录到5-羟色胺综合征,其中8例(89%)以维拉佐酮为主要药物。
- 病例系列中4例急性维拉佐酮中毒患者全部出现5-羟色胺综合征。
证据类型、等级与局限
- 证据类型:回顾性数据库综述及病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 维拉佐酮过量(包括单药摄入)与5-羟色胺综合征相关,诊治维拉佐酮摄入患者时应考虑5-羟色胺能毒性及适当治疗(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vilazodone is an antidepressant with selective serotonin reuptake inhibition and partial 5HT1A agonism. Serotonin syndrome is believed to be due to excessive stimulation of 5-HT2A and 5-HT1A receptors, resulting in the clinical triad of altered mentation, autonomic instability and neuromuscular abnormalities. The goal of this study is to define serotonergic effects after vilazodone exposure.
METHODS: A retrospective review of two databases: the American Association of Poison Controls Centers' National Poison Data System (NPDS) and the American College of Medical Toxicology's Toxicology Investigators Consortium (ToxIC Registry). A case series of four patients from one medical toxicology service is also presented.
RESULTS: During the 52-month study period, a total of 3192 vilazodone human exposures were reported to NPDS. Of these, 1734 (54%) were isolated vilazodone cases. The clinical effects of vilazodone toxicity included drowsiness (20%), vomiting (14%), tachycardia (11%) and agitation (10%). Most patients (71%) had symptoms for between 2 and 24 h, though some (14%) remained symptomatic for more than 24 h. The most common treatment was intravenous fluids (15%) and the most serious intubation (2%). From the ToxIC Registry, a total of 23 cases of vilazodone exposures were identified. Of these, 17 (74%) had vilazodone listed as the first (primary) agent and 10 (43%) involved vilazodone-only ingestions. Nine (39%) cases documented serotonin syndrome; and most (8/9; 89%) listed vilazodone as the primary agent. All (n = 4) subjects in the case series with acute vilazodone toxicity had serotonin syndrome.
CONCLUSIONS: Vilazodone overdose, including vilazodone-only ingestions, are associated with serotonin syndrome. Serotonergic toxicity and appropriate treatments should be considered when caring for patients with vilazodone ingestions.
参考来源
- Heise CW, Malashock H, Brooks DE, et al. A review of vilazodone exposures with focus on serotonin syndrome effects. Clin Toxicol (Phila). 2017. PMID: 28594246. doi:10.1080/15563650.2017.1332369
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。